
Seaport Therapeutics, Inc. Common Stock (SPTX) Stock Ticker
Market factors today
Unlock the full SPTX picture
About Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
SPTX stock facts
| Ticker symbol | SPTX |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.2B |
| CEO | Daphne Zohar |
| Employees | 58 |
| Headquarters | Boston, MA, US |
| IPO date | 2026-05-01 |
| Website | www.seaporttx.com |
What you can see for SPTX on Tickr
Live SPTX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the SPTX report.
Rankings
FAQ
What is the ticker symbol for Seaport Therapeutics, Inc. Common Stock?
The ticker symbol for Seaport Therapeutics, Inc. Common Stock is SPTX, listed on the NASDAQ Global Market.
What is SPTX?
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs,…